allAfrica.com on MSN8h
Africa: A Jab That Could Protect Against HIV for a Year At a Time, and Other Highlights From Major Conference
A single shot of a new formulation of the antiretroviral drug lenacapavir could potentially provide protection against HIV ...
Zacks.com on MSN23h
GILD Stock Down on Report of Cut in HIV Prevention Spending
Gilead Sciences takes a hit after a Wall Street Journal reports state that the Trump administration is looking to slash ...
The Zacks Analyst Blog Highlights Sarepta Therapeutics, Incyte, Gilead Sciences and VTv Therapeutics
Among these, Sarepta Therapeutics crashed following a report of a patient's death after treatment with Elevidys. Incyte also declined after study data disappointed investors. Shares of Sarepta ...
IPPMEDIA18h
HIV prevention injection finishes early safety trial
A NEW injection that could prevent HIV infection has successfully completed an early safety trial, according to a report in The Lancet medical journal. The injection, known as Lenacapavir, works by ...
Applied Clinical Trials Online2h
Tecentriq Falls Short of Primary Endpoint in IMvoke010 Trial for Locally Advanced Head and Neck Cancer
Phase III IMvoke010 trial found that maintenance treatment with Tecentriq (atezolizumab) did not significantly improve ...
Johns Hopkins Medicine23h
HIV and AIDS
AIDS (acquired immunodeficiency syndrome) is caused by the human immunodeficiency virus (HIV). This kills or impairs cells of the immune system and progressively destroys the body's ability to fight ...
IPPMEDIA18h
TACAIDS urges mining firms in Kahama to introduce HIV prevention programmes
THE Tanzania Commission for AIDS (TACAIDS) has urged mining companies in Kahama District, Shinyanga Region, to introduce male circumcision and preventive treatment programmes to curb new HIV ...